Target
FANCA
1 product, 10 indications
Indications
platinum-resistant high-grade serous ovarian cancer (1 products)
advanced squamous non-small-cell lung cancer (1 products)
recurrent or metastatic head and neck squamous cell carcinoma (1 products)
Metastatic Castration-Resistant Prostate Cancer (1 products)
recurrent or metastatic nasopharyngeal cancer (1 products)
Newly diagnosed advanced ovarian cancer (1 products)
Early stage epithelial ovarian cancer (1 products)
Advanced or recurrent ovarian cancer (1 products)
Ovarian cancer, primary peritoneal cancer, fallopian tube cancer (1 products)
Ovarian Cancer (1 products)
Loading...
1 drug
10 abstracts
Abstract
A clinical-genetic (CG) circulating tumor DNA (ctDNA)-based prognostic model for predicting overall survival (OS) in men with metastatic castrate-resistant prostate cancer (mCRPC) treated with potent androgen receptor inhibition (Alliance).Org: Department of Biostatistics and Bioinformatics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine, Duke University Medical Center, Duke University Department of Biostatistics and Bioinformatics,
Abstract
Discovery of a novel non-negative matrix factorization (NMF)-based homologous recombination deficiency (HRD) score and subsequent exploration in TALAPRO-2 (TP-2), a phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).Org: Pfizer Oncology Global Medical Affairs,
Abstract
Predictive gene signature for trabectedin efficacy in advanced soft‐tissue sarcoma: A Spanish group for research in sarcoma (GEIS) study.Org: Health Research Institute-Fundación Jiménez Díaz University Hospital, Autonomous University of Madrid (IIS-FJD, UAM), Madrid, Spain, Instituto de Biomedicina de Sevilla, Seville, Spain, University Hospital Miguel Servet, Zaragoza, Spain, University Hospital Gregorio Marañon, Madrid, Spain, Complejo Asistencial Universitario de Leon, Leon, Spain,
Abstract
TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations.Org: University of Paris-Saclay, Peter MacCallum Cancer Centre, Melbourne, Australia, National Cancer Center Hospital East, Kashiwa, Japan, Vall d’Hebron University Hospital/VHIO, Barcelona, Spain,
Abstract
Presence of somatic/germline homologous recombination repair (HRR) mutations and outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) receiving first‑line (1L) treatment stratified by BRCA status.Org: Janssen, Janssen Pharmaceuticals, Janssen Research & Development, Janssen-Cilag B.V., Janssen Pharmaceutica NV,
Abstract
Chemotherapeutic sensitivity in colorectal cancer expressing low RNA of wild type homologous recombination genes.Org: Mayo Clinic Arizona, Phoenix, AZ, Caris Life Sciences, Irving, TX, Mayo Clinic, Department of Medicine, Duke University Medical Center, Caris MPI,
Abstract
Pathogenic germline variants in patients with endometrial cancer across diverse ancestries.Org: Gynecologic Medical Oncology Service, Department of Medicine, Icahn School of Medicine at Mount Sinai, Memorial Sloan Kettering Cancer Center, Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA,
Abstract
Targeting germline or somatic DNA repair defects (beyond BRCA) in pancreatic cancer with niraparib: A phase II study (NIRA-PANC).Org: University of Kansas Cancer Center, Kansas City, KS, Westwood, The University of Kansas Medical Center, Kansas City, MO, University of Kansas Medical Center, Department of Biostatistics & Data Science,
Abstract
Implementing a germline testing program using fingernail specimens for patients with hematologic malignancies and initial clinical findings.Org: Memorial Sloan Kettering Cancer Center,
Abstract
Comprehensive genomic analysis for homologous recombination deficiency in pancreatic cancer.Org: Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea,